Precigen ActoBio Announces Positive Topline Results from Phase 1b Study of AG019 ActoBiotics™, A Novel Therapy Designed to Address the Underlying Cause of Type 1 Diabetes
Go back to Precigen ActoBio Announces Positive Topline Results from Phase 1b Study of AG019 ActoBiotics™, A Novel Therapy Designed to Address the Underlying Cause of Type 1 Diabetes| (NASDAQ: PGEN) | Delayed: 7.70 -0.08 (1.03%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $7.78 | 52 Week High | $ | |||
| Open | $7.84 | 52 Week Low | $ | |||
| Day High | $7.91 | P/E | N/A | |||
| Day Low | $7.63 | EPS | $ | |||
| Volume | 1,824,825 | |||||
